Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

se of cancer death in the United States, in both men and women.[iii]  It is estimated that more than 140,000 people will be diagnosed with CRC in 2011, and nearly 50,000 people will die from the disease.[iv] Approximately 50 percent of colon cancer patients will be diagnosed with metastases (most commonly to the liver) either at the time of diagnosis or due to recurrent disease.[v]

About Regorafenib

Regorafenib is an investigational oral multi-kinase inhibitor targeting angiogenic, stromal and oncogenic kinases[vi] and is currently being investigated in clinical trials for its potential to treat patients with various tumor types.

Regorafenib is an investigational agent and is not approved by the FDA, EMA or other health authorities. 

Regorafenib is one of several cancer compounds in Bayer's development pipeline.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.  The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements
This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, the expanded access program, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related t
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SOUTH PLAINFIELD, N.J. , Nov. 21, 2014  PTC ... announce that the 2014 Legend of Technology Award for Vision, ... Peltz , Ph.D., Chief Executive Officer. This award recognizes an ... industry in New Jersey for several ... Legend of Technology Award," stated Stuart Peltz , Ph.D., ...
(Date:11/21/2014)... MONTREAL , Nov. 21, 2014 /PRNewswire/ ... that the European Medicines Agency (EMA) has ... the company,s lead product candidate, for the ... is a rare, severely disabling genetic disease ... tissue swelling (flare-ups) and new abnormal bone ...
(Date:11/21/2014)... 20, 2014  Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, announced today that it ... support a strong launch of Edwards Lifesciences Foundation,s new ... improve the global communities where its employees live and ... giving will exceed $8 million, including more than $7 ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
... 1, 2011 Cherokee Uniforms, a leading provider of medical ... its annual Inspired Comfort Award . The award provides ... above and beyond their call of duty to make a ... its inception in 2003, more than 9,000 healthcare professionals have ...
... Source Precision Medicine, Inc., dba SourceMDx ("SourceMDx") has assigned ... of the firm Finn, Warnke & Gayton, LLP to be ... Source MDx® is an industry leader in developing simple blood ... cancer by measuring specific RNA transcripts in blood. RNA is ...
Cached Medicine Technology:Cherokee Inspired Comfort Award Calls for Healthcare Professional Nominations 2Cherokee Inspired Comfort Award Calls for Healthcare Professional Nominations 3Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP 2
(Date:11/22/2014)... 2014 Domestic farmgate milk and ... 2009-10, due to a fall in demand for ... products amid the global financial crisis. However, these ... Australian dairy manufacturers on the international scene. Strong ... supply growth, primarily due to supply constraints in ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... been filed on behalf of patients who allegedly developed ... move forward in the federal multidistrict litigation now underway ... Liebhard LLP reports. According to court documents, the litigation ... at 10:00 a.m. The Court has directed Lead Counsel ...
(Date:11/22/2014)... November 22, 2014 Recently, UWDress.com is ... wedding guest dresses . In addition, the company has ... , As a leading online supplier of wedding ... beautiful outfits. The unusual best wedding guest gowns are ... the amazing designs, this new selection is famous for ...
(Date:11/22/2014)... November 22, 2014 Sandbridge Capital, ... investments in the consumer brand sector, acquired a ... will be used to help fund BackJoy’s global ... rollout, particularly its proprietary apparel and footwear lines. ... BackJoy’s Board of Directors. , BackJoy is a ...
(Date:11/22/2014)... 2014 “Greenfield Naturals” was featured on ... , which features the latest and coolest technology products ... reporter for NewsWatch, conducted the product review and shared ... of your water. , From pollution to hazardous substances ... everything is done to remove these chemicals, especially in ...
Breaking Medicine News(10 mins):Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2
... Nov. 19 2009 has been a monumental year ... "moneyvation," from QUITPLAN Services, QuitCash Challenge, helped the 31-year-old ... win The Challenge. Nearly 2,000 Minnesotans, including Doug, attempted ... to win the $5,000 grand prize. , On Thursday, ...
... , Official Statement by Teamsters General President Jim ... President Jim Hoffa issued the following statement today about the ... higher-cost health plans that will mean a huge middle-class tax ... that would impose an excise tax on insurers for higher-cost ...
... , FAIRFIELD, N.J., Nov. 19 Monogram Energy, Inc. ... completed the acquisition of Triad Therapeutics, Inc. ("Triad"), which ... the terms of the Stock Purchase and Recapitalization Agreement, ... of Triad in exchange for approximately 95% ownership to ...
... who directs the University of Southern California Center ... effort to evaluate robots as exercise coaches for adults ... elderly. The effort, entitled "Robot Motivator: Towards Adaptive ... influence of virtual social characters on people,s motivation to ...
... , New Video Educates Kids on How to Prevent ... learn the five things that they can do to prevent the ... a new music video released today by the Department of Health. ... the simple ways to prevent H1N1 flu in a manner that ...
... WASHINGTON, Nov. 19 Now that a bill has been ... of the Democratic Caucus to vote to allow debate to ... promise of quality, affordable health care for all. , "Majority ... forward," said USAction Program Director Alan Charney. "Now it,s time ...
Cached Medicine News:Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 2Health News:First-Time Father-to-Be Quits Smoking, Wins $5,000 in The QuitCash Challenge(TM) 3Health News:Monogram Energy, Inc. Acquires Triad Therapeutics, Inc. 2Health News:Pennsylvania Department of Health Releases H1N1 Flu Prevention Music Video 2Health News:60 Votes: Democratic Caucus Must Move Forward With Promise of Quality, Affordable Health Care for All With a Public Insurance Option 2
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
... PADDLE RETRACT™ 12 mm instrument has application ... colorectal and other endoscopic procedures for retracting ... liver. , ,The ENDO PADDLE RETRACT™ ... the distal end of the instrument and ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... the widest offering of single-use instruments on the ... 43cm lengths for Bariatric Surgery. , Dual ... insulation covers the pivot points to reduce the ... 4mm universal cord, which eliminates gapping at connection ...
Medicine Products: